John Lechleiter News
Most Popular John Lechleiter Story
Is Lilly betting the farm on its high-stakes Alzheimer's gamble?
Now that the patent cliff has arrived right on time for Eli Lilly ($LLY), the big question this year is whether or not its massive gamble on the Alzheimer's drug solanezumab will pay off. That's Read more...
Latest Headlines
- February 2, 2012
- January 31, 2012
- November 22, 2011
- June 23, 2011
- February 10, 2011
- February 7, 2011
- October 1, 2010
- August 20, 2010
- August 18, 2010
- February 25, 2010
- October 23, 2009
- April 6, 2009
- March 31, 2009
- October 15, 2008
- October 6, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
